Yicheng (Alex) Liu
About Yicheng (Alex) Liu
Yicheng (Alex) Liu is a Clinical Trial Manager at Arcus Biosciences, where he has worked since 2023. He has a background in life sciences and biotechnology, with previous roles at Texas A&M University, the University of Minnesota, and Reata Pharmaceuticals.
Work at Arcus Biosciences
Yicheng (Alex) Liu has been serving as a Clinical Trial Manager at Arcus Biosciences since 2023. In this role, he oversees the planning and execution of clinical trials, ensuring compliance with regulatory requirements and company protocols. His responsibilities include managing trial timelines, coordinating with cross-functional teams, and monitoring trial progress to meet project objectives.
Previous Experience in Clinical Research
Before joining Arcus Biosciences, Liu held several positions in clinical research. He worked at Reata Pharmaceuticals, Inc. as a Clinical Study Manager for two months in 2023, after serving as an Associate Clinical Study Manager from 2021 to 2023. He also gained experience as a Clinical Trial Associate at Reata Pharmaceuticals from 2018 to 2021. Prior to his tenure at Reata, Liu was a Research Fellow at the University of Minnesota from 2014 to 2015 and a Research Associate at Texas A&M University from 2012 to 2014.
Education and Expertise
Liu holds a Bachelor's degree in Life Science from National Taiwan Normal University, where he studied from 2004 to 2008. He furthered his education at Texas A&M University, earning a Master's degree in Biotechnology from 2011 to 2013. His academic background provides a strong foundation for his work in clinical trials and research.
Career Timeline
Yicheng (Alex) Liu's career in clinical research spans over a decade. He began as a Research Associate at Texas A&M University from 2012 to 2014, followed by a Research Fellow position at the University of Minnesota from 2014 to 2015. He then joined Reata Pharmaceuticals, Inc. as a Clinical Trial Associate from 2018 to 2021, progressing to Associate Clinical Study Manager until 2023. Liu transitioned to Arcus Biosciences in 2023, marking a significant step in his career.